‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

Kyle LaHucik

Senior Reporter

A Canadian biotech creating bioprinted tissue therapeutics for type 1 diabetes, obesity and other endocrine and metabolic disorders has raised $115 million in a Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Gene editing startup Scribe Therapeutics lets go of staff as it preps for the clinic

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Resilience cuts 120 employees at a former bluebird gene therapy site

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

‘Too el­e­gant to ig­nore’: No­vo-al­lied As­pect Biosys­tems nabs $115M for bio­print­ed tis­sue ther­a­pies

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies